The pathobiology of splicing

Ninety‐four percent of human genes are discontinuous, such that segments expressed as mRNA are contained within exons and separated by intervening segments, called introns. Following transcription, genes are expressed as precursor mRNAs (pre‐mRNAs), which are spliced co‐transcriptionally, and the flanking exons are joined together to form a continuous mRNA. One advantage of this architecture is that it allows alternative splicing by differential use of exons to generate multiple mRNAs from individual genes. Regulatory elements located within introns and exons guide the splicing complex, the spliceosome, and auxiliary RNA binding proteins to the correct sites for intron removal and exon joining. Misregulation of splicing and alternative splicing can result from mutations in cis‐regulatory elements within the affected gene or from mutations that affect the activities of trans‐acting factors that are components of the splicing machinery. Mutations that affect splicing can cause disease directly or contribute to the susceptibility or severity of disease. An understanding of the role of splicing in disease expands potential opportunities for therapeutic intervention by either directly addressing the cause or by providing novel approaches to circumvent disease processes. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  J. Bocco,et al.  A new role for the Krüppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function , 2004, Oncogene.

[2]  G. Ito,et al.  Krüppel-Like Factor 6 Is Frequently Down-Regulated and Induces Apoptosis in Non-Small Cell Lung Cancer Cells , 2004, Cancer Research.

[3]  D. Hanck,et al.  A profile of alternative RNA splicing and transcript variation of CACNA1H, a human T-channel gene candidate for idiopathic generalized epilepsies. , 2006, Human molecular genetics.

[4]  A. Żarnecki Global analysis of , 1999, hep-ph/9904334.

[5]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[6]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[7]  J L Haines,et al.  Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .

[8]  S. Friedman,et al.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. , 2005, Cancer research.

[9]  Gheorghe Paun,et al.  Splicing , 2019, Bull. EATCS.

[10]  J. Fletcher,et al.  KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. , 2004, The Journal of molecular diagnostics : JMD.

[11]  D. Cox,et al.  A comparison of the mutation spectra of Menkes disease and Wilson disease , 2003, Human Genetics.

[12]  M. Carmo-Fonseca,et al.  The emerging role of splicing factors in cancer , 2008, EMBO reports.

[13]  C. Seoighe,et al.  Genome-wide survey of allele-specific splicing in humans , 2008, BMC Genomics.

[14]  Lili Wan,et al.  SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing , 2008, Cell.

[15]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[16]  Xiang-Dong Fu,et al.  Functional integration of transcriptional and RNA processing machineries. , 2008, Current opinion in cell biology.

[17]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[18]  C. Lorson,et al.  An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. , 2000, Human molecular genetics.

[19]  H. Erdjument-Bromage,et al.  Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. , 1999, Molecular cell.

[20]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[21]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[22]  D. Housman,et al.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Krzysztof Sobczak,et al.  Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA , 2009, Science.

[24]  J. Castle,et al.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart , 2008, Proceedings of the National Academy of Sciences.

[25]  H. Erdjument-Bromage,et al.  Purification and Characterization of the Human Elongator Complex* , 2002, The Journal of Biological Chemistry.

[26]  Dirk G Kieback,et al.  Expression of splicing factors in human ovarian cancer. , 2004, Oncology reports.

[27]  Gil Ast,et al.  Comparative analysis detects dependencies among the 5' splice-site positions. , 2004, RNA.

[28]  S. Cannon,et al.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. , 2002, Molecular cell.

[29]  Gil Ast,et al.  Alternative splicing and disease , 2008, RNA biology.

[30]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Naylor,et al.  Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9 , 2001, Science.

[32]  G. Fuller,et al.  A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors , 2005, Oncogene.

[33]  Z. Tümer,et al.  Mutation spectrum of ATP7A, the gene defective in Menkes disease. , 1999, Advances in experimental medicine and biology.

[34]  L. Comai,et al.  MBNL1 Is the Primary Determinant of Focus Formation and Aberrant Insulin Receptor Splicing in DM1* , 2005, Journal of Biological Chemistry.

[35]  C. Wijmenga,et al.  Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes , 2007, Journal of Medical Genetics.

[36]  B. Rubin,et al.  The Molecular Basis of Familial Dysautonomia: Overview, New Discoveries and Implications for Directed Therapies , 2007, NeuroMolecular Medicine.

[37]  J. Manley,et al.  A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy , 2003, Nature Genetics.

[38]  M. Merville,et al.  Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. , 2006, Molecular cell.

[39]  J. Martignetti,et al.  The role of KLF6 and its splice variants in cancer therapy. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[41]  Pamela A Silver,et al.  Global analysis of mRNA splicing. , 2007, RNA.

[42]  Keith J. Johnson,et al.  Myotonic dystrophy: Another case of too many repeats? , 1992, Human mutation.

[43]  J. Hampe,et al.  Single base‐pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing , 2007, Human mutation.

[44]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[45]  J. Lueck,et al.  Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. , 2007, The Journal of clinical investigation.

[46]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  John Calvin Reed,et al.  BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.

[48]  Simon C Watkins,et al.  Somatic reversion/suppression of the mouse mdx phenotype in vivo , 1990, Journal of the Neurological Sciences.

[49]  J. Manley,et al.  hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. , 2007, Human molecular genetics.

[50]  P. Byers,et al.  X-linked cutis laxa: defective cross-link formation in collagen due to decreased lysyl oxidase activity. , 1980, The New England journal of medicine.

[51]  S. Edwards,et al.  Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications , 2004, Cellular and Molecular Life Sciences CMLS.

[52]  B. Wieringa,et al.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy , 2009, Proceedings of the National Academy of Sciences.

[53]  M. Clarke,et al.  Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. , 1995, Cancer research.

[54]  J. Gusella,et al.  Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. , 2003, American journal of human genetics.

[55]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[56]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[57]  Thomas W. Glover,et al.  Isolation of a partial candidate gene for Menkes disease by positional cloning , 1993, Nature Genetics.

[58]  S. Friedman,et al.  KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer , 2001, Science.

[59]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[60]  Guey-Shin Wang,et al.  Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. , 2007, Molecular cell.

[61]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[62]  S. Packman,et al.  Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase , 1993, Nature Genetics.

[63]  S. Lazoff,et al.  Skeletal dysplasia, occipital horns, diarrhea and obstructive uropathy- a new hereditary syndrome. , 1975, Birth defects original article series.

[64]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[65]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[66]  Guey-Shin Wang,et al.  Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.

[67]  T. Dörk,et al.  Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping , 2001, The EMBO journal.

[68]  O. Olopade,et al.  Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. , 1997, The cancer journal from Scientific American.

[69]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[70]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[71]  S. Packman,et al.  Similar splicing mutations of the Menkes/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse. , 1995, American journal of human genetics.

[72]  D. Cleveland,et al.  Rethinking ALS: The FUS about TDP-43 , 2009, Cell.

[73]  S. Stamm,et al.  Substances that can change alternative splice-site selection. , 2008, Biochemical Society transactions.

[74]  Xun Hu,et al.  Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 , 2009, Science.

[75]  Johnston Rb The mechanism of bacterial killing by normal and chronic granulomatous disease leukocytes. , 1975 .

[76]  Tyson A. Clark,et al.  Nova regulates brain-specific splicing to shape the synapse , 2005, Nature Genetics.

[77]  W. Rizzo,et al.  Mitochondrial fatty-acid oxidation disorders. , 2008, Seminars in pediatric neurology.

[78]  J. Venables Unbalanced alternative splicing and its significance in cancer , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[79]  R. Guigó,et al.  Are splicing mutations the most frequent cause of hereditary disease? , 2005, FEBS letters.

[80]  Leo J. Lee,et al.  Current-generation high-throughput sequencing: deepening insights into mammalian transcriptomes. , 2009, Genes & development.

[81]  M. Genuardi,et al.  CDKN2A germline splicing mutation affecting both p16ink4 and p14arf RNA processing in a melanoma/neurofibroma kindred , 2001, Genes, chromosomes & cancer.

[82]  Anthony P. Monaco,et al.  Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein , 1993, Nature Genetics.

[83]  T. Cooper,et al.  Pre-mRNA splicing and human disease. , 2003, Genes & development.

[84]  M. Herlyn,et al.  Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Amemiya,et al.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. , 1992, Science.

[86]  G. van Ommen,et al.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. , 2007, RNA.

[87]  Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. , 2007, American journal of human genetics.

[88]  D. Goldstein,et al.  Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus , 1994, Nature Genetics.

[89]  S. Dhanasekaran,et al.  KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. , 2008, The Journal of clinical investigation.

[90]  L. Bonetta RNA-Based Therapeutics: Ready for Delivery? , 2009, Cell.

[91]  Z. Tümer,et al.  Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. , 2000, American journal of human genetics.

[92]  Lili Wan,et al.  RNA and Disease , 2009, Cell.

[93]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[94]  S. Friedman,et al.  Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1 , 2004, Cancer Research.

[95]  T. Vulliamy,et al.  Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. , 1993, American journal of human genetics.

[96]  Stefan Stamm,et al.  Regulation of Alternative Splicing by Reversible Protein Phosphorylation* , 2008, Journal of Biological Chemistry.

[97]  D. Schaid,et al.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. , 2005, Cancer research.

[98]  T. Cooper,et al.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy , 2001, Nature Genetics.

[99]  T. Cooper,et al.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. , 2002, Molecular cell.

[100]  Hensin Tsao,et al.  Melanoma and genetics. , 2009, Clinics in dermatology.

[101]  M. Swanson,et al.  Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. , 2006, Human molecular genetics.

[102]  C. Burge,et al.  Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia , 2007, Human mutation.

[103]  B. Rubin,et al.  Familial dysautonomia is caused by mutations of the IKAP gene. , 2001, American journal of human genetics.

[104]  D. Cooper,et al.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences , 1992, Human Genetics.

[105]  Huda Y. Zoghbi,et al.  Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles , 2005, Nature Reviews Genetics.

[106]  C Maayan,et al.  Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. , 2001, American journal of human genetics.

[107]  J. Lucas,et al.  Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35 , 2004, Journal of Biological Chemistry.

[108]  Lee T. Sam,et al.  Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.

[109]  Elisa de Stanchina,et al.  Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. , 2006, American journal of human genetics.

[110]  W. Hauswirth,et al.  A Muscleblind Knockout Model for Myotonic Dystrophy , 2003, Science.

[111]  Fei Liu,et al.  Molecular Neurodegeneration BioMed Central Review Tau exon 10 alternative splicing and tauopathies , 2008 .

[112]  C. Burge,et al.  Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. , 2008, RNA.

[113]  J. Valcárcel,et al.  Alternative pre-mRNA splicing: the logic of combinatorial control. , 2000, Trends in biochemical sciences.